Table 1 Demographic and clinical characteristics of participants.

From: Effects and safety of virtual reality-based mindfulness in patients with psychosis: a randomized controlled pilot study

Characteristics

VBM (n = 33)

VR control (n = 28)

P value

Sex

  

1

 Male

15(45.45%)

13(46.43%)

 

 Female

18(54.55%)

15(53.57%)

 

Age (years)

32.94 ± 11.00

31.32 ± 10.37

0.559

Education (years)

13.73 ± 2.07

13.77 ± 1.76

0.935

DUP (months)

15.47 ± 27.68

15.24 ± 20.81

0.971

DI (months)

114.48 ± 104.59

107.00 ± 107.81

0.785

Diagnosis

  

0.352

 Schizophrenia

28(84.85%)

21(75%)

 

 Schizophreniform disorder

1(3.03%)

1(3.57%)

 

 Schizoaffective disorder

1(3.03%)

3(10.71%)

 

 Psychotic disorder NOS

3(9.09%)

1(3.57%)

 

 Delusional disorder

0(0%)

2(7.14%)

 

 Chlorpromazine equivalent dose (mg)

508.75 ± 385.86

399.46 ± 359.35

0.260

  1. DUP Duration of untreated psychosis, DI duration of illness, VBM virtual reality-based mindfulness intervention.
Back to article page